Asia-Pacific Vaccine Excellence Awards
Celebrating Asia-Pacific's Best in Vaccines
Asia-Pacific Vaccine Excellence Awards (AVEA) 2021 is to recognize the Asian vaccine manufacturer and the achievements it has made over the past year. Despite the COVID-19 pandemic, the industry has overcome adversity and continues with its R&D excellence.
The purpose of AVEA2021 is to recognize the outstanding achievements of vaccine & supply chain experts, organizations, and the newest technologies in Asia. Featuring top vaccine industry leaders, along with the latest advances in technologies and best practices in R&D and manufacturing, the Asia Pacific Vaccine Excellence Award applauds extraordinary leaders & trendsetters of today and inspires innovators of tomorrow.
Nikolai Petrovsky Vaxine Pty Ltd
Jerome H. Kim International Vaccine Institute
Yiwu He The University of Hong Kong
What is the purpose of having the Asia-Pacific Vaccine Excellence Awards?
The Asia-Pacific Vaccine Excellence Awards (AVEA2021) seeks to recognize organizations within the Asia Pacific Region who have engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality, and safety in vaccine development and manufacturing. Nominations are free and open to all members of the industry. You don’t have to be a subscriber, an advertiser, a sponsor or a client of IMAPAC’s conferences to be nominated or to win.
What is the Judging Process for the awards?
Two rounds of call for nominations are conducted. Nominations are then passed on to the judging panel. The judging panel is made up of a team of 3 judges who assess the applications online, before making their final decisions on the winners. Finalists will be announced to the industry and a voting process begins. The final category winners will be determined via industry-wide voting over 3 weeks and in the event of a tie, the judging panel intervenes to make the final decision based on the company’s track record over the past years.